Genentech agrees to purchase Regor's breast cancer CDK inhibitors for $850M upfront, with potential milestones, in a Q4 2024 deal.

Genentech, part of the Roche Group, has agreed to purchase Regor Pharmaceuticals' next-generation CDK inhibitors for breast cancer for $850 million upfront, with potential additional payments tied to future milestones. Genentech will handle clinical development, manufacturing, and commercialization. The acquisition is expected to finalize in Q4 2024, while Regor will continue managing its current Phase 1 trials and other oncology assets.

September 30, 2024
7 Articles

Further Reading